Paper Details

  1. Home
  2. Paper Details

Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.

Author:

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Allogeneic bone marrow transplantation (alloBMT) was associated with significantly longer survival compared to conventional chemotherapy in patients with chronic myeloid leukemia, regardless of age or risk.
Paper Details　
Original Abstract of the Article :
PURPOSE: To monitor treatment results and survival in chronic myeloid leukemia after allogeneic bone marrow transplantation (alloBMT) and the introduction of interferon alpha (IFNalpha). PATIENTS AND METHODS: Disease course was monitored in 840 patients younger than 56 years who were registered ont...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/10561226

データ提供：米国国立医学図書館（NLM）

Allogeneic Bone Marrow Transplantation: A Powerful Tool in the Fight Against Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a serious hematologic malignancy, and effective treatment strategies are crucial. This research investigates the long-term outcomes of allogeneic bone marrow transplantation (alloBMT) and interferon alpha (IFNalpha) therapy in patients with CML.

The study found that alloBMT, particularly when performed early in the course of the disease, was associated with significantly longer survival compared to conventional chemotherapy or IFNalpha therapy. These findings highlight the importance of early intervention and the potential benefits of alloBMT in CML management.

Allogeneic Bone Marrow Transplantation: A Life-Saving Intervention for CML

The study's results demonstrate the effectiveness of alloBMT in treating CML, particularly in younger patients and those with intermediate or high risk. This emphasizes the importance of considering alloBMT as a viable treatment option for CML, especially when early intervention is possible.

Early Intervention and Allogeneic Bone Marrow Transplantation: Crucial for CML Management

CML is a serious condition, and prompt and effective treatment is essential. This research highlights the importance of early intervention and the potential benefits of alloBMT, particularly for younger patients and those at higher risk. It underscores the need for comprehensive evaluation and personalized treatment plans for patients with CML.

Dr. Camel's Conclusion

This research, like a camel navigating the shifting sands of CML treatment, has revealed the immense power of allogeneic bone marrow transplantation. The study's findings provide valuable insights into the long-term outcomes of various treatment approaches, offering guidance for clinicians and hope for patients. Early intervention and personalized treatment plans are crucial in the management of CML, and this research underscores the importance of considering alloBMT as a potentially life-saving intervention.

Date :
  1. Date Completed 2000-01-13
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

10561226

DOI: Digital Object Identifier

10561226

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.